Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial
European Journal of Cancer · 2026-08 · 244 · 116888
DOI: 10.1016/j.ejca.2026.116888 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Karim Fizazi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Centre Oscar Lambret, Institute Gustave Roussy, University of Paris-Saclay, Lille, France. Electronic address: k-fizaz…. Hauptthemen laut MEDLINE: Quality of Life, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Receptor Antagonists. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer Healthcare, Bayer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Medicine, Centre Oscar Lambret, Institute Gustave Roussy, University of Paris-Saclay, Lille, France. Electronic address: k-fizazi@o-lambret.fr.
- Genitourinary Oncology Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
- Division of Hematology-Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.
- Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, Hematology/Oncology, New York, NY, USA.
- Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Förderung
- Bayer Healthcare
- Bayer
Zitieren
APA
Fizazi, K., Smith, M. R., Hussain, M., Saad, F., Sternberg, C. N., David Crawford, E., Aragon-Ching, J. B., Schostak, M., Tutrone, R., Morgans, A. K., Sentana-Lledo, D., Joensuu, H., Mohamed, A. F., Littleton, N., Srinivasan, S., Buttkewitz, Y., Li, R., Kuss, I., & Tombal, B. (2026). Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. European Journal of Cancer, 244, 116888. https://doi.org/10.1016/j.ejca.2026.116888
Vancouver
Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, et al. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. European Journal of Cancer. 2026;244:116888. doi:10.1016/j.ejca.2026.116888
BibTeX
@article{Fizazi2026,
author = {Fizazi, Karim and Smith, Matthew R and Hussain, Maha and Saad, Fred and Sternberg, Cora N and David Crawford, E and Aragon-Ching, Jeanny B and Schostak, Martin and Tutrone, Ronald and Morgans, Alicia K and Sentana-Lledo, Daniel and Joensuu, Heikki and Mohamed, Ateesha F and Littleton, Natasha and Srinivasan, Shankar and Buttkewitz, Yvonne and Li, Rui and Kuss, Iris and Tombal, Bertrand},
title = {Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial},
journal = {European Journal of Cancer},
year = {2026},
volume = {244},
pages = {116888},
doi = {10.1016/j.ejca.2026.116888}
}
EUVIMED